For research use only. Not for therapeutic Use.
Cantuzumab ravtansine（Cat No.:I042145）is an investigational antibody-drug conjugate (ADC) that targets the protein CD74, which is expressed on cancer cells, particularly in hematologic malignancies like multiple myeloma and lymphoma. The antibody component of cantuzumab ravtansine binds specifically to CD74, allowing the drug to be selectively delivered to cancer cells. The conjugated drug component, DM4, is a cytotoxic agent that is released inside the tumor cell, disrupting its ability to divide and survive. It is being studied in clinical trials for its potential to treat various cancers with reduced side effects compared to traditional chemotherapy.
| CAS Number | 868747-45-9 |
| Purity | ≥95% |
